In this study, we focused on the effects of GluA2-GAPDH disruption as a model to elucidate the distinct astrocytic changes regulated by this complex, which may also represent possible cellular mechanisms in ameliorating MS symptoms. This evidence concerns the gene GAPDH and myeloid sarcoma.